ArticleJournal of immunology (Baltimore, Md. : 1950)2017
Varied Role of Ubiquitylation in Generating MHC Class I Peptide Ligands.
Abstract read
In one paragraph
Article in Journal of immunology (Baltimore, Md. : 1950), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Inhibition of cellular NEDDylation partially alters the MHC class I immunopeptidome.Journal of immunology (Baltimore, Md. : 1950) · 2026Article
- HLA Class I Expression Is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.Molecular cancer research : MCR · 2026Article
- PROTACs in cancer immunotherapy: a minireview.Biochemical Society transactions · 2025Review
- The UBA1-STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade.Cancer discovery · 2025Article
- Alternate MHC I Antigen Presentation Pathways Allow CD8+ T-cell Recognition and Killing of Cancer Cells in the Absence of β2M or TAP.Cancer immunology research · 2025Article
- The ubiquitin-like modifier FAT10 is not essential for MHC-I antigen presentation.Frontiers in immunology · 2025Article
- Current Landscape of Cancer Immunotherapy: Harnessing the Immune Arsenal to Overcome Immune Evasion.Biology · 2024Review
- Quantitative measurement of the requirement of diverse protein degradation pathways in MHC class I peptide presentation.Science advances · 2023Article
- The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC.Nature cancer · 2023Article
- Review
- Implications of the Essential Role of Small Molecule Ligand Binding Pockets in Protein-Protein Interactions.The journal of physical chemistry. B · 2022Article
- Know thy immune self and non-self: Proteomics informs on the expanse of self and non-self, and how and where they arise.Proteomics · 2021Review
- Beneficial autoimmunity improves cancer prognosis.Nature reviews. Clinical oncology · 2021Review
- Direct Conjugation of NEDD8 to the N-Terminus of a Model Protein Can Induce Degradation.Cells · 2021Article
- Article
- Viruses, cancer and non-self recognition.Open biology · 2021Review
- A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion.Nature reviews. Immunology · 2021Review
- Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.Frontiers in immunology · 2021Review
- The Effect of Interferons on Presentation of Defective Ribosomal Products as HLA Peptides.Molecular & cellular proteomics : MCP · 2021Article
- Immunopeptidomic Analysis Reveals That Deamidated HLA-bound Peptides Arise Predominantly from Deglycosylated Precursors.Molecular & cellular proteomics : MCP · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Jiajie WeiLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Damien ZankerT Cell Laboratory, School of Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia.ORCID 0000-0003-1163-9902
Anthony R Di CarluccioT Cell Laboratory, School of Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia.ORCID 0000-0002-6925-3829
Margery G SmelkinsonBiological Imaging Section, Research Technologies Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.ORCID 0000-0001-7777-5574
Kazuyo TakedaMicroscopy and Imaging Core Facility, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993; and.
Mina O SeedhomLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Devin DershLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
James S GibbsLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Ning YangLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.ORCID 0000-0001-5121-7208
Ajit JadhavChemical Genomics Center, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD 20892.
Weisan ChenT Cell Laboratory, School of Molecular Science, La Trobe University, Bundoora, Victoria 3086, Australia.ORCID 0000-0002-5221-9771
Jonathan W YewdellLaboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892; jyewdell@niaid.nih.gov.ORCID 0000-0003-2123-6189
Funding
Infectious Diseases Research Technologies Core - BethesdaZICAI001051 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI CHERRY, JAMES · 2009 to 2025
$226.1MTranslation in ImmunityZIAAI001210 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI YEWDELL, JONATHAN W · 2016 to 2025
$12.5MPROCESSING OF VIRAL PROTEINS FOR T CELL RECOGNITIONZ01AI000542 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI YEWDELL, JONATHAN W · 1988 to 2008
$1.6MDELIVERY OF ANTIGENS TO THE MHC CLASS PROCESSING PATHWAYZ01AI000653 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI YEWDELL, JONATHAN W · 1992 to 2008
$1.6MIntramural NIH HHS Z01 AI000542Intramural NIH HHS Z01 AI000653
Abstract
CD8
Indexed as
Antigen PresentationAnimalsCell LineCytosolEnzyme InhibitorsHistocompatibility Antigens Class IHumansInfluenza A virusKineticsLigandsMiceMonitoring, ImmunologicNucleosidesPeptidesPyrazolesPyrimidinesEnzyme InhibitorsHistocompatibility Antigens Class ILigandsNucleosidesPeptidesPyrazolesPyrimidinesSulfidesSulfonamidesTAK-243
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.